Rabbani Syed | Pharmaco-Oncology | Innovative Research Award

Innovative Research Award

Rabbani Syed
King Saud University, Saudi Arabia

Rabbani Syed
Affiliation King Saud University
Country Saudi Arabia
Scopus ID 35751491100
Documents 95
Citations 1,703
h-index 21
Subject Area Pharmaco-Oncology
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0003-4695-0645

The Innovative Research Award recognizes research activity that contributes to the development of new knowledge, methodologies, or applications within a defined academic discipline. This profile presents the available research information associated with Rabbani Syed of King Saud University, Saudi Arabia, in the context of the International Research Awards on Oncology and Cancer Research.

Abstract

This academic recognition profile documents the supplied research information of Rabbani Syed, affiliated with King Saud University in Saudi Arabia. The researcher is associated with the subject area of Pharmaco-Oncology and has been proposed in connection with the Innovative Research Award. The available bibliometric information includes 95 documents, 1,703 citations, and an h-index of 21. These indicators offer a measurable description of scholarly activity but do not, by themselves, establish the originality or practical effectiveness of individual studies. Further evaluation requires examination of publications, research methods, and documented contributions.

Keywords

Keywords: Innovative Research Award, Rabbani Syed, King Saud University, Saudi Arabia, Pharmaco-Oncology, cancer research, oncology, pharmaceutical research, bibliometrics, scholarly publications, therapeutic research, research recognition.

Introduction

Pharmaco-Oncology encompasses research involving medicines, drug mechanisms, therapeutic development, and pharmacological strategies relevant to cancer care. Innovation in this field may involve the discovery of candidate compounds, investigation of drug responses, improvements in drug-delivery systems, or the evaluation of treatment-related biological mechanisms. Research recognition in this area requires consideration of the scientific question, methodological rigor, reproducibility, and potential relevance to oncology. [2]

Research Profile

Rabbani Syed is identified in the supplied information as a researcher affiliated with King Saud University, Saudi Arabia. The provided Scopus author identifier is 35751491100, while the ORCID identifier is 0000-0003-4695-0645. The supplied profile statistics indicate 95 documents, 1,703 citations, and an h-index of 21. These figures should be interpreted with reference to the date of retrieval and the specific author record. [1]

Research Contributions

The supplied subject classification places the researcher within Pharmaco-Oncology. However, detailed information about specific research projects, experimental findings, patented technologies, clinical investigations, or methodological innovations has not been provided. Consequently, individual contributions cannot be independently described in detail. A comprehensive assessment would examine the originality of the research questions, the quality of the evidence, and the relevance of reported findings to oncology and pharmaceutical science. [3]

Publications

The supplied information reports a total of 95 documents associated with the researcher’s academic record. A complete publication list, including article titles, journals, publication dates, co-authors, and digital object identifiers, was not supplied for this profile. The Scopus author record may provide a starting point for examining indexed publications and related citation information. Publication-level verification is necessary before attributing specific scientific findings or research achievements.

Research Impact

The reported citation count of 1,703 and h-index of 21 provide quantitative indicators of the researcher’s documented scholarly visibility. Citation measures can assist in describing patterns of academic attention, but they may be influenced by publication age, disciplinary practices, collaboration patterns, and database coverage. They should therefore be considered alongside qualitative evidence, including research reproducibility, scientific influence, and documented applications. [4]

Award Suitability

The Innovative Research Award is associated with research that demonstrates originality and meaningful advancement within a relevant field. The supplied affiliation, subject area, publication count, citation count, and h-index provide contextual information for an academic review. A formal award assessment should additionally consider the nominee’s documented innovations, supporting publications, research significance, and compliance with the event’s eligibility criteria. The available information alone does not establish the outcome of an award evaluation.

Conclusion

Rabbani Syed is identified in the supplied data as a King Saud University researcher working in the subject area of Pharmaco-Oncology. The reported record includes 95 documents, 1,703 citations, and an h-index of 21. These metrics summarize selected aspects of scholarly activity. Further information about research innovations, individual publications, and documented scientific outcomes would be required to develop a more comprehensive academic assessment in relation to the Innovative Research Award.

References

  1. Elsevier. (n.d.). Scopus author details: Rabbani Syed, Author ID 35751491100. Scopus.https://www.scopus.com/authid/detail.uri?authorId=35751491100
  2. National Cancer Institute. (n.d.). Drug therapy and cancer treatment research. National Cancer Institute.https://www.cancer.gov/about-cancer/treatment/types
  3. Hanahan, D. (2022). Hallmarks of cancer: New dimensions. Cancer Discovery, 12(1), 31–46.https://doi.org/10.1158/2159-8290.CD-21-1059
  4. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences, 102(46), 16569–16572.https://doi.org/10.1073/pnas.0507655102
  5. ORCID. (n.d.). ORCID: Connecting research and researchers. ORCID.https://orcid.org/0000-0003-4695-0645

LEANDRO RESENDE | Oncology and precision medicine | Innovative Research Award

Innovative Research Award

LEANDRO RESENDE
Rede Dor

LEANDRO RESENDE
Affiliation Rede Dor
Country Brazil
Scopus ID 57188977624
Documents 5
Citations 35
h-index 3
Subject Area Oncology and precision medicine
Event International Research Awards on Oncology and Cancer Research
Scopus Author Profile

LEANDRO RESENDE is a researcher affiliated with Rede Dor in Brazil whose documented scholarly profile is associated with oncology and precision medicine.The Innovative Research Award profile presents this research activity within the broader context of contemporary cancer science, where molecular characterization, individualized treatment strategies, biomarkers, and evidence-based clinical decision-making increasingly intersect. Precision oncology seeks to connect biological information with clinically meaningful therapeutic choices. [1]

Abstract

The Innovative Research Award profile recognizes the research record of LEANDRO RESENDE, affiliated with Rede Dor, Brazil, in the field of oncology and precision medicine. The documented Scopus profile reports five scholarly documents, 35 citations, and an h-index of 3. [1] These indicators provide a bibliometric snapshot of published research and citation activity.Within modern oncology, precision medicine emphasizes the integration of molecular, clinical, and pathological information to support more individualized approaches to cancer investigation and treatment.

Keywords

  • Innovative Research Award
  • Oncology
  • Precision Medicine
  • Cancer Research
  • Biomedical Research
  • Research Impact

Introduction

Cancer research increasingly depends on interdisciplinary approaches that connect molecular biology, clinical medicine, pathology, genomics, and computational analysis. Precision medicine has developed as an important framework for identifying biological differences between tumors and using those differences to inform research and therapeutic strategies. [3]Against this background, researchers working across oncology contribute to a continually expanding evidence base.

Research Profile

LEANDRO RESENDE is affiliated with Rede Dor in Brazil and is represented in Scopus under Author ID 57188977624. The supplied profile records five documents, 35 citations, and an h-index of 3. [1] The stated subject area is oncology and precision medicine, placing the research profile within a clinically and scientifically significant field.

Research Contributions

Contemporary cancer frameworks emphasize multiple interacting characteristics of malignant disease, including genomic instability, cellular signaling, immune interactions, and the tumor microenvironment. [3]The documented bibliometric record offers measurable evidence of scholarly dissemination, while the specific scientific significance of individual publications should be evaluated through their methods, findings, citations, and subsequent use by other researchers.

Publications

The supplied Scopus record identifies five documents associated with the researcher. [1] Because complete publication titles, journal information, publication years, and DOI identifiers were not supplied with the profile data, this article does not assign specific publication details that cannot be independently established from the provided record.

Research Impact

The reported total of 35 citations indicates that the indexed documents have been cited within the scholarly literature. The h-index of 3 further describes a citation distribution in which at least three documents have each received at least three citations, subject to the indexing and counting methodology used by the database. [1]Citation metrics are useful descriptive measures but do not independently determine scientific quality or societal impact.

Award Suitability

The supplied research profile is aligned thematically with an award focused on oncology and cancer research because the stated subject area is oncology and precision medicine. The documented publication and citation record provides an objective basis for describing established scholarly activity. [1]Final award assessment should be based on the organizer’s published eligibility criteria, submitted evidence, peer or committee evaluation, and the originality and significance of the candidate’s research.

Conclusion

LEANDRO RESENDE’s supplied academic profile documents research activity associated with Rede Dor, Brazil, and the fields of oncology and precision medicine. The Scopus record reports five documents, 35 citations, and an h-index of 3, providing a concise bibliometric description of the researcher’s indexed scholarly output. [1]The Innovative Research Award profile places these activities within the wider development of precision oncology and evidence-based cancer research.

References

  1. Elsevier. (n.d.). Scopus author details: LEANDRO RESENDE, Author ID 57188977624. Scopus.
    https://www.scopus.com/pages/authors/57188977624
  2. National Cancer Institute. (n.d.). Precision Medicine in Cancer Treatment. National Cancer Institute.
    https://www.cancer.gov/about-cancer/treatment/types/precision-medicine
  3. Hanahan, D. (2022). Hallmarks of Cancer: New Dimensions. Cell, 185(1), 31–41. DOI: 10.1016/j.cell.2021.12.029.
    https://doi.org/10.1016/j.cell.2021.12.029
  4. Ashley, E. A. (2016). Towards precision medicine. Nature Reviews Genetics, 17, 507–522. DOI: 10.1038/nrg.2016.86.
    https://doi.org/10.1038/nrg.2016.86
  5. International Research Awards on Oncology and Cancer Research. (n.d.). Official Award Website.
    https://oncology.pencis.com/

Assoc Prof Dr.Marwa Muhammad Abu-Serie Ali – Targeted Cancer Therapy – Best Researcher Award

Assoc Prof Dr.Marwa Muhammad Abu-Serie Ali - Targeted Cancer Therapy - Best Researcher Award

SRTA city - Egypt

AUTHOR PROFILE

Scopus

EARLY ACADEMIC PURSUITS:

Marwa Muhammad Abu-Serie Ali initiated her academic journey in the field of biochemistry, obtaining a Bachelor's degree from Alexandria University, Egypt, with honors. She continued her academic pursuits with a Master's degree in Biochemistry from the same university in 2008. Later, in 2014, Marwa achieved a significant milestone by completing her Ph.D. in the Biochemistry Department at the Faculty of Science, Alexandria University, Egypt. Her doctoral thesis focused on a model for drug assessment of colon cancer induced in murine cells.

PROFESSIONAL ENDEAVORS:

Marwa's professional journey encompasses various roles, starting from a Delegated Demonstrator at Alexandria University to her current position as an Associate Professor in the Medical Biotechnology Department at the Genetic Engineering and Biotechnology Research Institute (GEBRI) in Egypt. She has consistently contributed to research and academia, progressing from Assistant Researcher to Researcher and eventually to her current leadership position as an Associate Professor.

CONTRIBUTIONS AND RESEARCH FOCUS ON TARGETED CANCER THERAPY

Marwa's research focus is on medical biotechnology, with specific interests in tageted cancer therapy studies. Her work includes projects such as the assessment of nanotherapeutic approaches in colon cancer, the development of anti-coronavirus agents, and the evaluation of novel anticancer agents. She has also explored the anti-tumor efficacy of various formulations against different types of carcinoma, emphasizing a comprehensive and innovative approach to cancer treatment.

IMPACT AND INFLUENCE:

Marwa has made significant contributions to the scientific community through her involvement in research projects funded by prestigious organizations like the Science & Technology Development Fund (STDF), Fulbright, and the Academy of Scientific Research and Technology Center (STC). Her work has not only expanded scientific knowledge but has also paved the way for potential breakthroughs in cancer treatment and the fight against infectious diseases.

ACADEMIC CITATIONS:

Marwa's academic work has likely garnered citations in various research publications, reflecting the impact of her contributions to the field of medical biotechnology. These citations signify the acknowledgment and recognition of her research by peers and fellow scientists.

LEGACY AND FUTURE CONTRIBUTIONS:

Marwa's legacy lies in her commitment to advancing knowledge in medical biotechnology, particularly in cancer research and antiviral drug development. Her future contributions are anticipated to further shape the landscape of biomedical research, potentially leading to breakthroughs in cancer treatment and viral therapeutics.

NOTABLE PUBLICATIONS

Anticancer activity of lactoferrin-coated biosynthesized selenium nanoparticles for combating different human cancer cells via mediating apoptotic effects.2023

Inhibitory effect of lactoferrin-coated zinc nanoparticles on SARS-CoV-2 replication and entry along with improvement of lung fibrosis induced in adult male albino rats.2023

Concurrent Tissue Engineering for Wound Healing in Diabetic Rats Utilizing Dual Actions of Green Synthesized CuO NPs Prepared from Two Plants Grown in Egypt.2023

 

Mr.Christopher Olowosoke – Targeted Cancer Therapy – Best Researcher Award

Mr.Christopher Olowosoke - Targeted Cancer Therapy - Best Researcher Award

Federal University of Technology Akure - Nigeria

AUTHOR PROFILE

Scopus

EARLY ACADEMIC PURSUITS

Christopher Busayo Olowosoke embarked on his academic journey with a focus on biotechnology. His dedication to academic excellence was evident during his West African Senior School Certificate Examination at Isefun Community Senior Secondary School, Lagos State, Nigeria, where he achieved a grade of Distinction in the Science stream. This early success set the stage for his future pursuits in the field of biotechnology and information technology.

PROFESSIONAL ENDEAVORS

With a passion for biotechnology and an interest in the chemistry of natural products and pharmacology, Christopher pursued his first degree at the Federal University of Technology, Akure, Ondo State, Nigeria. Graduating with an outstanding grade of 4.73/5.00 in Biotechnology in 2020, he showcased his commitment to academic excellence. His undergraduate thesis, "Identification of pungency-associated genes in some indigenous Nigerian hot pepper varieties," demonstrated his engagement with cutting-edge research.

CONTRIBUTIONS AND RESEARCH FOCUS ON TARGETED CANCER THERAPY

As a Student Research Assistant at the Federal University of Technology, Akure, Christopher actively contributed to research in the Departments of Biochemistry, Biotechnology, and Microbiology from 2017 to 2021. His involvement in in vivo, in vitro, and in silico procedures for diabetes and  targeted cancer therapy underscored his commitment to addressing metabolic and cellular proliferation dysregulation, aligning with Sustainable Development Goal 3 (SDG 3). Additionally, his work on the phyto-treatment of diabetes using Andrographic paniculata showcased his dedication to innovative therapeutic approaches.

IMPACT AND INFLUENCE

Christopher's impact extended beyond the laboratory. As a Laboratory Research Assistant at Chrisland University Biotechnology Department from 2022 to the present, he played a pivotal role in organizing practical sessions and providing training in bioinformatics and molecular biology for undergraduates. His leadership as the Founder of B.Khrease Academic Consult since 2018 highlights his commitment to facilitating student projects, mentorship, and collaboration with academic experts.

ACADEMIC CITES

Christopher's research contributions are recognized through his publications. His paper titled "Multiregulator of EZH2-PPARs Therapeutic Targets" was published in Applied Biochemistry and Biotechnology in 2023. This publication addresses critical aspects of pancreatic insulin production and cancer dysregulation. The link to his full publication list on ResearchGate (https://www.researchgate.net/profile/Christopher-Olowosoke/research) reflects his ongoing scholarly pursuits.

LEGACY AND FUTURE CONTRIBUTIONS

Christopher's legacy includes leadership roles, such as being the Founder of B.Khrease Academic Consult and serving as the Promotional and Development Committee Head at the Institute of Bioinformatics and Molecular Therapeutic (IBMT) since 2021. His active participation in conferences, workshops, and professional webinars, as well as affiliations with prestigious societies, showcases his commitment to staying at the forefront of biotechnological advancements.

AWARDS/GRANT

Christopher's achievements are acknowledged through various awards and grants, including being a beneficiary of the American Society for Nutrition Early Career Professional Mentoring Program in 2023 and securing the second position in the Peeref International Best Poster Presentation in the same year. His involvement in securing the TETFUND Grant Award for the Biotechnology Department in 2022 and the UNESCO-ICB Scholarship in 2020 further demonstrates his capacity to contribute significantly to his field.

NOTABLE PUBLICATION

Multi-regulator of EZH2-PPARs Therapeutic Targets: A Hallmark for Prospective Restoration of Pancreatic Insulin Production and Cancer Dysregulation.